|
|
|
|
|
|
|
12.01.26 - 18:03
|
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Business Wire)
|
|
|
Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025
Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025
Preliminary PMO net product revenues totaled $259.2 million for the fourth quarter and $965.6 million for full-year 2025
Preliminary year-end 2025 cash, cash equivalents, restricted cash and investments balance of approximately $953.8 million
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Financial Update* (preliminary and unaudited)
Total net product revenue of $369.6 million for the fourth qu...
|
|
|
|
|
31.12.25 - 23:21
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in the fourth quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 55,118 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta's common stock.
About Sarepta Therapeutics
Sarepta is on an urgent ...
|
|
|
|
|
|
|
18.12.25 - 12:15
|
Sarepta-Aktie: Das sind positive Entwicklungen! (Sharedeals)
|
|
|
Die Aktie von Sarepta Therapeutics hat in den vergangenen Wochen deutlich an Aufmerksamkeit gewonnen, nachdem regulatorische und strategische Entwicklungen neue Perspektiven für das Unternehmen eröffnet haben. Besonders im Bereich der Duchenne-Muskeldystrophie zeichnet sich ein struktureller Impuls ab, der über kurzfristige Kursreaktionen hinausgehen dürfte. Ein regulatorischer Beschluss mit weitreichenden Folgen Das US-Gesundheitsministerium HHS hat entschieden, die […]
The post Sarepta-Aktie: Das sind positive Entwicklungen! first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
